Patients with Alzheimer’s disease (AD) and clinically overlapping neurodegenerative diseases are classified molecularly using the A/T/N classification system. Apart from fluid biomarkers and structural MRI, A/T/N assessment incorporates β-amyloid-PET (A), tau-PET (T), and [18F]FDG-PET (N). We evaluated if dynamic featu...
Johannes S. Gnörich, J. Kusche-Palenga, Agnes Kling et al.· Molecular Neurodegeneration· 0 citations
While nigrostriatal dopaminergic cell loss is the pathological hallmark of Parkinson's disease, it is well-known that dopamine deficiency cannot fully explain the clinical severity or disease progression. Emerging data suggest that resilience, i.e. the brain's capacity to maintain function despite pathology, plays a ke...
M. C. Ruppert-Junck, T. van Eimeren, Kathrin Giehl et al.· Brain : a journal of neurolo...· 0 citations
INTRODUCTION
Network attack tolerance (NAT) measures the brain's ability to sustain information flow despite the loss of critical brain regions. In Parkinson's disease (PD), NAT has been linked to cognitive and motor function. However, it remains unclear how dopaminergic degeneration shapes NAT, and whether it relates...
Adrian L. Asendorf, Verena Dzialas, T. van Eimeren et al.· Movement Disorders· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.